SUNNYVALE, Calif., Sept. 24, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a California-based development-stage biotechnology developing new treatments and diagnostics for Parkinson's disease (PD) centered around its patented therapeutic protein MANF, today announced the release of a 2-page research report by OneMedPlace Research. The report can be found at http://www.onemedplace.com/reports/Amarantus_Research_Analysis.pdf. The report states: "Treatment with MANF prior to inducing PD-like conditions in animals protected the subjects from the onset of neuron degeneration. Even more impressively, in animals where Parkinson's was already present, treatment with MANF provided restorative benefits that included regaining motor function, as well as the maintenance and increase in function of the neurons that were still present. Cumulatively, these studies provide strong evidence that MANF has the potential to serve as a first-in-class curative treatment for degenerative neurological disorders that include PD. Amarantus is currently in the design and development stages to move MANF into clinical trials." The report also states: "Amarantus owns the license for Power3 Medical Products' NuroPro Blood Test as it relates to Parkinson's disease. NuroPro is a diagnostic platform for the early detection of neurodegenerative diseases. The PD application of this diagnostic has completed proof-of-concept and Phase I clinical validation studies." About Amarantus BioSciences, Inc. Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"). For further information please visit www.amarantus.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.